LYSSA
MCID: RBS001
MIFTS: 56

Rabies (LYSSA) malady

Categories: Rare diseases, Infectious diseases, Neuronal diseases

Aliases & Classifications for Rabies

Aliases & Descriptions for Rabies:

Name: Rabies 12 50 56 52 41 3 42 14 69
Lyssa 12 50

Characteristics:

Orphanet epidemiological data:

56
rabies
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe),<1/1000000 (Europe); Age of onset: All ages; Age of death: any age;

Classifications:



External Ids:

Disease Ontology 12 DOID:11260
ICD10 33 A82 A82.9
ICD9CM 35 071
MeSH 42 D011818
NCIt 47 C28182
Orphanet 56 ORPHA770
MESH via Orphanet 43 D011818
UMLS via Orphanet 70 C0034494
ICD10 via Orphanet 34 A82.0 A82.1 A82.9
UMLS 69 C0034494

Summaries for Rabies

MedlinePlus : 41 rabies is a deadly animal disease caused by a virus. it can happen in wild animals, including raccoons, skunks, bats and foxes, or in dogs, cats or farm animals. people get it from the bite of an infected animal. in people, symptoms of rabies include fever, headache and fatigue, then confusion, hallucinations and paralysis. once the symptoms begin, the disease is usually fatal. a series of shots can prevent rabies in people exposed to the virus. you need to get them right away. if an animal bites you, wash the wound well; then get medical care. to help prevent rabies vaccinate your pet. rabies vaccines are available for dogs, cats and farm animals don't let pets roam don't approach stray animals. animals with rabies might be aggressive and vicious, or tired and weak centers for disease control and prevention

MalaCards based summary : Rabies, also known as lyssa, is related to bile duct adenocarcinoma and encephalitis, and has symptoms including fever, headache and prickling or itching sensation at the site of bite. An important gene associated with Rabies is PML (Promyelocytic Leukemia), and among its related pathways/superpathways are Innate Immune System and Akt Signaling. The drugs Atovaquone and chloroquine have been mentioned in the context of this disorder. Affiliated tissues include brain, spinal cord and testes, and related phenotypes are cellular and immune system

CDC : 3 Rabies is a preventable viral disease of mammals most often transmitted through the bite of a rabid animal. The vast majority of rabies cases reported to the Centers for Disease Control and Prevention (CDC) each year occur in wild animals like raccoons, skunks, bats, and foxes.

Disease Ontology : 12 A viral infectious disease that results_in inflammation located in brain or located in spinal cord, has material basis in Rabies virus, which is transmitted_by bite of an infected animal, or transmitted_by contact of mucous membranes with saliva of an infected animal. The infection has symptom fever, has symptom headache, has symptom prickling or itching sensation at the site of bite, has symptom anxiety, has symptom confusion, has symptom agitation, has symptom delirium, has symptom difficulty swallowing, has symptom hydrophobia, and has symptom paralysis.

Wikipedia : 71 Rabies is a viral disease that causes inflammation of the brain in humans and other mammals. Early... more...

Related Diseases for Rabies

Diseases related to Rabies via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 87)
id Related Disease Score Top Affiliating Genes
1 bile duct adenocarcinoma 10.2 ALB CD40LG
2 encephalitis 10.1
3 methylmalonic aciduria and homocystinuria, cblj type 10.1 MX1 STAT1 STAT2
4 colloid adenoma 10.1 ALB CD40LG
5 estrogen excess 10.1 ALB CD40LG
6 neuronitis 10.1
7 hepatitis c virus 10.1 IRF3 MX1 TLR3
8 heart conduction disease 10.1 CD40LG STAT1 STAT2
9 freiberg's disease 10.1 ALB CD40LG
10 benign deep fibrous histiocytoma 10.1 ALB CD40LG TLR3
11 inner ear disease 10.1 ALB CD40LG NGFR
12 chondrodysplasia punctata, tibia-metacarpal type 10.0 CD40LG IGHM
13 striatonigral degeneration 10.0 ALB CD40LG
14 gastroduodenitis 10.0 CD40LG STAT1 STAT2 TLR3
15 early yaws 10.0 ALB CCL5 CD40LG
16 israeli tick typhus 10.0 CCL5 CD40LG
17 amyotrohpic lateral sclerosis type 22 9.9 CD40LG CXCL10
18 acute chest syndrome 9.9 ALB CCL5 CD40LG
19 depressed scar 9.9 ALB CD40LG STAT1 STAT2 TLR3
20 infundibulocystic basal cell carcinoma 9.9 CD40LG MX1
21 dyskeratosis congenita 9.9 ALB CD40LG CXCL10
22 eczematous dermatitis of eyelid 9.8 CXCL10 IRF3 STAT1 TLR3
23 viral encephalitis 9.8
24 foodborne botulism 9.8 ALB CD40LG CXCL10
25 bladder signet ring cell adenocarcinoma 9.8 CCL5 CXCL10 MX1
26 sexual masochism 9.8 CCL5 CXCL10 STAT1 TLR3
27 tetanus 9.8
28 transmitted_by 9.8
29 complex regional pain syndrome 9.7 CCL5 CD40LG CXCL10
30 cerebritis 9.7
31 stomatitis 9.7
32 neuroblastoma 9.7
33 japanese encephalitis 9.7
34 malaria 9.7
35 st. louis encephalitis 9.7
36 poliomyelitis 9.7
37 acute disseminated encephalomyelitis 9.7
38 transverse myelitis 9.7
39 serotonin syndrome 9.7
40 erythema multiforme 9.7
41 psychotic disorder 9.7
42 newcastle disease 9.7
43 myelitis 9.7
44 lichen planus 9.7
45 vaccinia 9.7
46 eastern equine encephalitis 9.7
47 purpura 9.7
48 advanced sleep phase syndrome, familial, 1 9.6 CCL5 CD40LG CXCL10 MX1
49 hyperimmunoglobulin syndrome 9.6 CCL5 CD40LG CXCL10 IRF3 STAT1
50 plantar fasciitis 9.6 CCL5 CD40LG CXCL10 IRF3 TLR3

Graphical network of the top 20 diseases related to Rabies:



Diseases related to Rabies

Symptoms & Phenotypes for Rabies

Symptoms:

12
  • fever
  • headache
  • prickling or itching sensation at the site of bite
  • anxiety
  • confusion
  • agitation
  • delirium
  • difficulty swallowing
  • hydrophobia
  • paralysis

Human phenotypes related to Rabies:

56 32 (show all 19)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 fever 56 32 Very frequent (99-80%) HP:0001945
2 seizures 56 32 Occasional (29-5%) HP:0001250
3 reduced consciousness/confusion 56 32 Occasional (29-5%) HP:0004372
4 diarrhea 56 32 Very frequent (99-80%) HP:0002014
5 nausea and vomiting 56 32 Very frequent (99-80%) HP:0002017
6 recurrent pharyngitis 56 32 Very frequent (99-80%) HP:0100776
7 depression 56 32 Very frequent (99-80%) HP:0000716
8 sudden cardiac death 56 32 Occasional (29-5%) HP:0001645
9 hallucinations 56 32 Very frequent (99-80%) HP:0000738
10 attention deficit hyperactivity disorder 56 32 Very frequent (99-80%) HP:0007018
11 anxiety 56 32 Very frequent (99-80%) HP:0000739
12 anorexia 56 32 Very frequent (99-80%) HP:0002039
13 migraine 56 32 Very frequent (99-80%) HP:0002076
14 paresthesia 56 32 Very frequent (99-80%) HP:0003401
15 insomnia 56 32 Very frequent (99-80%) HP:0100785
16 cerebral palsy 56 32 Frequent (79-30%) HP:0100021
17 vocal cord paresis 56 32 Very frequent (99-80%) HP:0001604
18 excessive salivation 56 32 Very frequent (99-80%) HP:0003781
19 behavioral abnormality 56 Very frequent (99-80%)

UMLS symptoms related to Rabies:


fever, pruritus

MGI Mouse Phenotypes related to Rabies:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 9.61 ALB CD40LG CXCL10 IKBKE IRF3 NCAM1
2 immune system MP:0005387 9.32 CCL5 CD40LG CXCL10 IKBKE IRF3 NGFR

Drugs & Therapeutics for Rabies

Drugs for Rabies (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 78)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Atovaquone Approved Phase 4 95233-18-4 74989
2
chloroquine Approved, Vet_approved Phase 4 54-05-7 2719
3
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
4
Proguanil Approved Phase 4 500-92-5 4923
5 Antibodies Phase 4,Phase 2,Phase 3,Phase 1
6 Immunoglobulins Phase 4,Phase 2,Phase 3,Phase 1
7 Vaccines Phase 4,Phase 2,Phase 3,Phase 1
8 gamma-Globulins Phase 4,Phase 2,Phase 3,Phase 1
9 Immunoglobulins, Intravenous Phase 4,Phase 2,Phase 3,Phase 1
10 Rho(D) Immune Globulin Phase 4,Phase 2,Phase 3,Phase 1
11 Anti-Bacterial Agents Phase 4,Phase 1
12 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
13 Antimetabolites Phase 4,Phase 2
14 Antirheumatic Agents Phase 4,Phase 2
15 Analgesics Phase 4
16 Analgesics, Non-Narcotic Phase 4
17 Anthelmintics Phase 4
18 Anti-Inflammatory Agents Phase 4
19 Anti-Inflammatory Agents, Non-Steroidal Phase 4
20 Antimalarials Phase 4,Phase 3
21 Antiparasitic Agents Phase 4,Phase 3
22 Antiprotozoal Agents Phase 4,Phase 3
23 Atovaquone, proguanil drug combination Phase 4
24 Chloroquine diphosphate Phase 4 50-63-5
25 Peripheral Nervous System Agents Phase 4
26
Amodiaquine Approved Phase 3 86-42-0 2165
27
Pyrimethamine Approved, Vet_approved Phase 3 58-14-0 4993
28
Sulfadoxine Approved Phase 3 2447-57-6 17134
29
Lactitol Phase 3 585-86-4 3871
30 Cathartics Phase 3
31 Gastrointestinal Agents Phase 3,Phase 2,Phase 1
32 Laxatives Phase 3
33 Renal Agents Phase 3
34
Aluminum hydroxide Approved Phase 2,Phase 1 21645-51-2
35
Abacavir Approved, Investigational Phase 2 136470-78-5 65140 441300
36
Cyclosporine Approved, Investigational, Vet_approved Phase 2 79217-60-0, 59865-13-3 5284373 6435893
37
Efavirenz Approved, Investigational Phase 2 154598-52-4 64139
38
Lamivudine Approved, Investigational Phase 2 134678-17-4 60825
39
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
40
Zidovudine Approved Phase 2 30516-87-1 35370
41 Antibodies, Monoclonal Phase 2
42
QS 21 Phase 2 141256-04-4
43 Adjuvants, Immunologic Phase 2,Phase 1
44 Antacids Phase 2,Phase 1
45 Anti-Ulcer Agents Phase 2,Phase 1
46 Antifungal Agents Phase 2
47 Anti-HIV Agents Phase 2
48 Anti-Retroviral Agents Phase 2
49 Antiviral Agents Phase 2,Phase 1
50 Calcineurin Inhibitors Phase 2

Interventional clinical trials:

(show top 50) (show all 96)
id Name Status NCT ID Phase
1 Persistence of Rabies Antibody 1-5 Years After the Post-exposure Prophylaxis With Vero Cell Antirabies Vaccine and Antibody Response to a Single Booster Dose Unknown status NCT01173302 Phase 4
2 Rabies Immune Plasma Booster Study Completed NCT01063140 Phase 4
3 The Protection Effect of Speeda® Rabies Vaccine for Human Use Completed NCT01827917 Phase 4
4 Immunogenicity and Safety of Rabies Vaccine, Administered With Two Different Simulated Post Exposure Schedules Completed NCT01365494 Phase 4
5 Immunogenicity and Safety of Verorab™ in Indian Population Completed NCT00260351 Phase 4
6 Immunogenicity of Rabies Vaccine for Pre Exposure Completed NCT02374814 Phase 4
7 A Study to Evaluate Persistence of Immune Responses After Post-exposure Prophylaxis of Rabipur® (Purified Chicken-embryo Cell Rabies Vaccine) in Chinese Children Completed NCT02991872 Phase 4
8 The Post-Marketing Safety and Immunogenicity Research of Speeda® Rabies Vaccine for Human Use Completed NCT01821911 Phase 4
9 Diagnostic Immunization With Rabies Vaccine in Patients With PID Recruiting NCT02490956 Phase 4
10 Effect of Antimalarial Drugs to Rabies Vaccine for Post-exposure Prophylaxis. Recruiting NCT02564471 Phase 4
11 Immunogenicity and Safety Study of A New Chromatographically Purified Vero Cell Rabies Vaccine With ID Regimen and ERIG Recruiting NCT01137045 Phase 4
12 Phase II/III Study of the Safety and Effectiveness of HRIG With Co-administration of Active Rabies Vaccine in Healthy Subjects Unknown status NCT02040090 Phase 2, Phase 3
13 Early Rabies Vaccine Immunization in Primary School Children Completed NCT01107275 Phase 3
14 Simplifying the Rabies Pre-exposure Vaccination Completed NCT01388985 Phase 3
15 Study of the Purified Vero Rabies Vaccine - Serum Free in Comparison With the Reference Purified Vero Rabies Vaccine Completed NCT01339312 Phase 3
16 Safety and Immunogenicity of Two Intradermal Rabies Vaccine Regimens Administered With and Without Human Rabies Immunoglobulin in Subjects ≥ 1 Years of Age Completed NCT02177032 Phase 3
17 A Phase 3 Clinical Trial for a Rabies Vaccine (Vero Cell) for Human Use in Healthy Chinese Subjects Completed NCT02491541 Phase 3
18 Purified Rabies Vaccine for Human Use (Chick-embryo Cell) Completed NCT00345319 Phase 3
19 Safety and Immunogenicity of 2 Different Vaccination Schedules of Rabies and Japanese Encephalitis Vaccines in Healthy Adult Subjects Completed NCT01662440 Phase 3
20 A Randomized, Open-label Study Comparing Two Different Rabies Vaccine Schedules in Chinese Children and Older Adults Completed NCT01680016 Phase 3
21 Safety and Immunogenicity (Non-inferiority) of a Purified Chick Embryo Cell Vaccine Vaccine Administered in Two Different Schedules (Conventional Versus Abbreviated Schedule) Completed NCT00825305 Phase 3
22 Safety and Immunogenicity of Freeze-dried Rabies Vaccine(MRC-5 Cell) in Chinese Humans Completed NCT02288286 Phase 3
23 A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults Completed NCT01466387 Phase 3
24 Safety and Immunogenicity of GSK Biologicals' Investigational Malaria Vaccine in HIV Infected Infants and Children Completed NCT01148459 Phase 3
25 Efficacy of GSK Biologicals' Candidate Malaria Vaccine 257049 Against Malaria Disease in Infants and Children in Africa Completed NCT00866619 Phase 3
26 Immunogenicity and Safety of Verorab® in a "One-week" Intradermal Post-exposure Prophylaxis Regimen Recruiting NCT01622062 Phase 3
27 Seasonal Malaria Vaccination (RTS,S/AS01) and Seasonal Malaria Chemoprevention (SP/AQ) Recruiting NCT03143218 Phase 3
28 A Phase 3 Clinical Trial to Evaluate Long-term Immunogenicity and Boostability of Purified Chick-Embryo Cell Rabies Vaccine in Adults Following Primary Series of Pre/Exposure Prophylaxis. Active, not recruiting NCT02545517 Phase 3
29 An Extended Follow up of a RTS,S/AS01E Malaria Vaccine Trial Active, not recruiting NCT00872963 Phase 2, Phase 3
30 Post-marketing Study of KamRAB Administered as a Single Dose With Active Rabies Vaccine in Children Exposed to Rabies Not yet recruiting NCT02912845 Phase 3
31 Single Center, Open Label, Follow up Study in Subjects Who Previously Received Rabies Vaccine as Simulated Post-Exposure Regimen Terminated NCT01067079 Phase 3
32 One-visit Multi-site Intradermal Rabies Vaccination - Dose Finding Unknown status NCT02276625 Phase 2
33 Immunogenicity, Efficacy and Safety Study of an MSP3-LSP (Long Synthetic Peptide) Malaria Vaccine Unknown status NCT00652275 Phase 2
34 Study of Purified Vero Rabies Vaccine and Rabies Human Diploid Cell Vaccine in a Simulated Rabies Post-exposure Regimen Completed NCT01877395 Phase 2
35 Purified Vero Rabies Vaccine-Serum Free Compared to Human Diploid Cell Vaccine in a Pre-exposure Prophylaxis Regimen Completed NCT01930357 Phase 2
36 Comparison of Purified Vero Rabies Vaccine, Serum Free With Human Diploid Cell Vaccine in Pre-exposure Use Completed NCT01784874 Phase 2
37 Efficacy and Safety of a PIKA Rabies Vaccine Containing the PIKA Adjuvant With an Accelerated Regimen Completed NCT02956421 Phase 2
38 Study of Purified Vero Rabies Vaccine Serum Free Compared With Reference Purified Vero Rabies Vaccine in Healthy Adults Completed NCT00948272 Phase 2
39 Rabies Virus Neutralizing Activity and Safety of CL184, a Monoclonal Antibody Cocktail, in Simulated Rabies Post-Exposure Prophylaxis in Healthy Adults Completed NCT01228383 Phase 2
40 Rabies Immunization Concomitant With JEV in Children Completed NCT00703521 Phase 2
41 Randomized Phase II Trial on Safety and Neutralizing Activity of CL184 and Rabies Vaccine Versus Human Rabies Immune Globulin (HRIG) and Rabies Vaccine in Children and Adolescents Completed NCT00708084 Phase 2
42 A Randomized Phase II Trial to Compare the Safety and Neutralizing Activity of CL184 in Combination With Rabies Vaccine vs. HRIG or Placebo in Combination With Rabies Vaccine in Healthy Adult Subjects Completed NCT00656097 Phase 2
43 Evalution of Immunogenicity, Safety and Booster Response of a Rabies Vaccine Administered Concomitantly With Japanese Encephalitis Vaccine in Toddlers Completed NCT00694460 Phase 2
44 Safety and Immunogenicity Study of Recombinant Human Rabies Immunoglobin (rhRIG) in Combination With Rabies Vaccine for Human Use With Human Rabies Immune Globulin (HRIG) in Combination With Rabies Vaccine for Human Use in Healthy Adult Subjects. Completed NCT02559921 Phase 2
45 Phase II AMA-1 Malaria Vaccine FMP2.1/AS02A Trial in Mali Completed NCT00460525 Phase 2
46 Double-blind, Randomized, Controlled Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine Completed NCT00223990 Phase 2
47 Efficacy of Malaria Vaccines in Kenyan Adults Completed NCT01666925 Phase 2
48 Efficacy of Candidate Malaria Vaccines in Senegalese Adults Completed NCT01658696 Phase 2
49 A Phase 1/2b Study of an Investigational Malaria Vaccination Strategy in 5-17 Month Old Infants and Children in Burkina Faso Completed NCT01635647 Phase 1, Phase 2
50 Efficacy and Safety of Dengue Vaccine in Healthy Children Completed NCT00842530 Phase 2

Search NIH Clinical Center for Rabies

Cochrane evidence based reviews: rabies

Genetic Tests for Rabies

Anatomical Context for Rabies

MalaCards organs/tissues related to Rabies:

39
Brain, Spinal Cord, Testes, Skin, Cortex, T Cells, B Cells

The Foundational Model of Anatomy Ontology organs/tissues related to Rabies:

18
Brain Or

Publications for Rabies

Articles related to Rabies:

(show top 50) (show all 718)
id Title Authors Year
1
Replacement of in vivo human rabies vaccine potency testing by in vitro glycoprotein quantification using ELISA - Results of an international collaborative study. ( 28081969 )
2017
2
Resurgence of rabies in Hungary during 2013-2014: An attempt to track the origin of identified strains. ( 28497505 )
2017
3
High Incidence of Human Rabies Exposure in Northwestern Tigray, Ethiopia: A Four-Year Retrospective Study. ( 28060935 )
2017
4
Type 1 Immune Mechanisms Driven by the Response to Infection with Attenuated Rabies Virus Result in Changes in the Immune Bias of the Tumor Microenvironment and Necrosis of Mouse GL261 Brain Tumors. ( 28461570 )
2017
5
Time to appreciate Avicenna's knowledge of rabies. ( 28503287 )
2017
6
A novel in vitro ELISA for estimation of glycoprotein content in human rabies vaccines. ( 28436708 )
2017
7
The Middle East and Eastern Europe rabies Expert Bureau (MEEREB) third meeting: Lyon-France (7-8 April, 2015). ( 28476258 )
2017
8
Sero-prevalence of virus neutralizing antibodies for rabies in different groups of dogs following vaccination. ( 28521804 )
2017
9
Human Rabies - Puerto Rico, 2015. ( 28056006 )
2017
10
Could the RTS,S/AS01 meningitis safety signal really be a protective effect of rabies vaccine? ( 28065475 )
2017
11
Targeting the central nervous system (CNS): a review of rabies virus-targeting strategies. ( 28514853 )
2017
12
Rabies Virus Infection Induces Microtubule Depolymerization to Facilitate Viral RNA Synthesis by Upregulating HDAC6. ( 28491824 )
2017
13
Rabies Tracing of Birthdated Dentate Granule Cells in Rat Temporal Lobe Epilepsy. ( 28470680 )
2017
14
Susceptibility of neuroblastoma cells to rabies virus may be affected by passage number. ( 28506631 )
2017
15
Fusion peptide improves stability and bioactivity of single chain antibody against rabies virus. ( 28068664 )
2017
16
Monosynaptic Tracing in Developing Circuits Using Modified Rabies Virus. ( 27943201 )
2017
17
Immunogenicity and Safety of Purified Vero Cell Rabies Vaccine (PVRV) under Zagreb 2-1-1 or 5-dose Essen regimen in Chinese adults aged 50 and above. ( 28045585 )
2017
18
Rabies surveillance in the United States during 2015. ( 28467751 )
2017
19
Organization of dopamine and serotonin system: Anatomical and functional mapping of monosynaptic inputs using rabies virus. ( 28476484 )
2017
20
A Pan-Lyssavirus Taqman Real-Time RT-PCR Assay for the Detection of Highly Variable Rabies virus and Other Lyssaviruses. ( 28081126 )
2017
21
Comprehensive Monosynaptic Rabies Virus Mapping of Host Connectivity with Neural Progenitor Grafts after Spinal Cord Injury. ( 28479302 )
2017
22
Correction: Management and modeling approaches for controlling raccoon rabies: The road to elimination. ( 28463964 )
2017
23
The Ilocos Norte Communities against Rabies Exposure Elimination Project in the Philippines: Epidemiological and Economic Aspects. ( 28484703 )
2017
24
Rabies Vaccination Targets for Stray Dog Populations. ( 28451589 )
2017
25
Indigenous Wildlife Rabies in Taiwan: Ferret Badgers, a Long Term Terrestrial Reservoir. ( 28497055 )
2017
26
Rescue of a wild-type rabies virus from cloned cDNA and assessment of the proliferative capacity of recombinant viruses. ( 28447192 )
2017
27
Investigating the effect of carbon source on rabies virus glycoprotein production in Pichia pastoris by a transcriptomic approach. ( 28523730 )
2017
28
Expression of interleukin-6 by a recombinant rabies virus enhances its immunogenicity as a potential vaccine. ( 28089546 )
2017
29
Serologic response in eight alpacas vaccinated by extralabel use of a large animal rabies vaccine during a public health response to a rabid alpaca in South Carolina. ( 27585106 )
2016
30
CNS infection safety signal of RTS,S/AS01 and possible association with rabies vaccine. ( 27115819 )
2016
31
Human rabies in monkey (Macaca mulatta) bite patients a reality in India now! ( 27178163 )
2016
32
Electrotherapy in the treatment of patients affected by rabies: experiments conducted at the "Maggiore" hospital of Milan in 1865. ( 28038493 )
2016
33
Supporting rabies control in India. ( 27660350 )
2016
34
The Rabies Virus L Protein Catalyzes mRNA Capping with GDP Polyribonucleotidyltransferase Activity. ( 27213429 )
2016
35
Host-pathogen evolutionary signatures reveal dynamics and future invasions of vampire bat rabies. ( 27621441 )
2016
36
Rabies Vaccination: Higher Failure Rates in Imported Dogs than in those Vaccinated in Italy. ( 27152896 )
2016
37
A novel rabies virus lipopeptide provides a better protection by improving the magnitude of DCs activation and T cell responses. ( 27182006 )
2016
38
Reduction of animal suffering in rabies vaccine potency testing by introduction of humane endpoints. ( 28040390 )
2016
39
Lichen planus after rabies vaccination: an example of isovaccinetopic response. ( 27653743 )
2016
40
One Health approach to cost-effective rabies control in India. ( 27994161 )
2016
41
Improved Monosynaptic Neural Circuit Tracing Using Engineered Rabies Virus Glycoproteins. ( 27149846 )
2016
42
The matrix protein of rabies virus binds to RelAp43 to modulate NF-I_B-dependent gene expression related to innate immunity. ( 28000711 )
2016
43
Quantitative Analysis of the Microtubule Interaction of Rabies Virus P3 Protein: Roles in Immune Evasion and Pathogenesis. ( 27649849 )
2016
44
T-705 as a potential therapeutic in rabies. ( 27190188 )
2016
45
Notes from the Field: Assessment of Health Facilities for Control of Canine Rabies - Gondar City, Amhara Region, Ethiopia, 2015. ( 27149318 )
2016
46
Impact of recombinant Drosophila S2 cell population enrichment on expression of rabies virus glycoprotein. ( 27216014 )
2016
47
Perspectives in Diagnosis and Treatment of Rabies Viral Encephalitis: Insights from Pathogenesis. ( 27324391 )
2016
48
Development and validation of a quantitative competitive ELISA for potency testing of equine anti rabies sera with other potential use. ( 27151880 )
2016
49
Quantitative Proteome Profiling of Street Rabies Virus-Infected Mouse Hippocampal Synaptosomes. ( 27155843 )
2016
50
Possible cures for clinical rabies: Are they already on the pharmacy shelf? ( 27555281 )
2016

Variations for Rabies

Expression for Rabies

Search GEO for disease gene expression data for Rabies.

Pathways for Rabies

Pathways related to Rabies according to GeneCards Suite gene sharing:

(show all 21)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.85 CCL5 CD40LG CXCL10 IFNA4 IKBKE IRF3
2
Show member pathways
13.24 CCL5 CD40LG CXCL10 IKBKE NGFR STAT1
3
Show member pathways
13.13 CCL5 CD40LG CXCL10 IFNA4 IRF3 MX1
4
Show member pathways
12.84 CCL5 IFNA4 IKBKE IRF3 STAT1 STAT2
5
Show member pathways
12.78 CCL5 CXCL10 IFNA4 IKBKE IRF3 STAT1
6
Show member pathways
12.58 CCL5 CXCL10 IFNA4 IKBKE IRF3
7
Show member pathways
12.48 CD40LG IKBKE PML STAT1
8
Show member pathways
12.48 CD40LG IKBKE IRF3 NGFR TLR3
9
Show member pathways
12.29 IFNA4 IRF3 MX1 NCAM1 PML STAT1
10
Show member pathways
12.12 IKBKE IRF3 STAT1 TLR3
11 12.1 CCL5 CD40LG CXCL10 IKBKE IRF3 NCAM1
12
Show member pathways
12.04 IFNA4 IRF3 MX1 STAT1 STAT2
13
Show member pathways
12.01 CCL5 CXCL10 IFNA4 IKBKE IRF3 MX1
14 11.93 NCAM1 NGFR STAT1
15 11.89 ALB NCAM1 NGFR
16
Show member pathways
11.78 STAT1 STAT2 TLR3
17 11.75 IFNA4 IKBKE IRF3 STAT1 STAT2 TLR3
18 11.69 IKBKE STAT1 STAT2
19 11.56 IFNA4 STAT1 STAT2
20 11.25 CXCL10 STAT1 STAT2
21
Show member pathways
11.03 IRF3 MX1 STAT1 STAT2

GO Terms for Rabies

Cellular components related to Rabies according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 9.26 CD40LG CXCL10 IGHM NCAM1
2 cell surface GO:0009986 9.02 CD40LG IGHM NCAM1 NGFR TLR3

Biological processes related to Rabies according to GeneCards Suite gene sharing:

(show all 23)
id Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.96 CCL5 CD40LG CXCL10 IKBKE NGFR
2 viral process GO:0016032 9.89 IRF3 NCAM1 PML STAT1 STAT2
3 inflammatory response GO:0006954 9.88 CCL5 CD40LG CXCL10 NGFR TLR3
4 innate immune response GO:0045087 9.8 IFNA4 IGHM IKBKE IRF3 MX1 PML
5 tumor necrosis factor-mediated signaling pathway GO:0033209 9.79 CD40LG NGFR STAT1
6 defense response GO:0006952 9.76 CXCL10 IFNA4 MX1 TLR3
7 negative regulation of angiogenesis GO:0016525 9.72 CXCL10 PML STAT1
8 response to cytokine GO:0034097 9.7 CCL5 PML STAT1
9 interferon-gamma-mediated signaling pathway GO:0060333 9.62 IRF3 NCAM1 PML STAT1
10 response to exogenous dsRNA GO:0043330 9.61 IFNA4 IRF3 TLR3
11 positive regulation of monocyte chemotaxis GO:0090026 9.6 CCL5 CXCL10
12 cellular response to interferon-beta GO:0035458 9.59 STAT1 TLR3
13 positive regulation of T cell migration GO:2000406 9.58 CCL5 CXCL10
14 I-kappaB phosphorylation GO:0007252 9.58 IKBKE TLR3
15 regulation of type I interferon-mediated signaling pathway GO:0060338 9.58 IFNA4 STAT1 STAT2
16 response to interferon-beta GO:0035456 9.57 IKBKE STAT1
17 response to virus GO:0009615 9.55 CCL5 CXCL10 IFNA4 MX1 TLR3
18 response to type I interferon GO:0034340 9.54 IKBKE MX1
19 TRIF-dependent toll-like receptor signaling pathway GO:0035666 9.54 IKBKE IRF3 TLR3
20 cellular response to dsRNA GO:0071359 9.51 IRF3 TLR3
21 type I interferon signaling pathway GO:0060337 9.35 IFNA4 IRF3 MX1 STAT1 STAT2
22 defense response to virus GO:0051607 9.23 CXCL10 IFNA4 IRF3 MX1 PML STAT1
23 apoptotic process GO:0006915 10 IRF3 MX1 NGFR PML STAT1

Molecular functions related to Rabies according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.26 CCL5 CD40LG CXCL10 IFNA4
2 identical protein binding GO:0042802 9.1 ALB IRF3 MX1 STAT1 STAT2 TLR3
3 protein binding GO:0005515 10 ALB CCL5 CD40LG CXCL10 IFNA4 IGHM

Sources for Rabies

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....